The role of pentoxifylline in erythropoietin-resistant anemia
Phase 3
- Conditions
- Kidney dialysis.Y84 Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
- Registration Number
- IRCT20100413003698N2
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
having the age of 18 years and more
receiving HD treatments at least for 3 months
receiving 4-hour HD treatments 3 times per week a
hemoglobin (Hb)<11 in at least 2 consecutive tests in a month
no change in EPO dose for at least 1 month before starting the study.
Exclusion Criteria
blood transfusion due to any reason in recent 3 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hemoglobin. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn to measure of hemoglobin.
- Secondary Outcome Measures
Name Time Method Erythrocyte sedimentation rate. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn.;C-reactive protein. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn.